GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Liver complications related to MASLD continue to increase around the world, particularly in economically disadvantaged countries.

If you're worried about keeping your kidneys in good health, look no further - a doctor known for sharing healthy eating ...

According to Dr SK Sarin, to prevent fatty liver disease, you should steer clear of foods that cause inflammation, such as ...

When Camryn Clements’ husband, an internal medicine doctor in training at the time, faced a series of health issues, the ...

PNN Greater Noida Uttar Pradesh [India] November 15 School of Medical Sciences and Research SMSR at Sharda Hospital ...

Diabetes is a metabolic disorder that develops when the body is unable to produce or effectively use insulin the hormone ...

Sunaina Roshan, Hrithik Roshan’s sister, has amazed fans with her 50-kg weight loss transformation despite battling grade 3 ...

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

Nearly three quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...